Treatment for Hereditary Tyrosinemia Type 1 - Input for Health Canada review of Orfadin and MDK-Nitisinone
Answers marked with a * are required.
This survey closed as of 5:00 ET on Friday, January 6, 2017. If you need assistance, please contact Melanie Kearns at mkearns@liver.ca.
 
 
 

 
 
Create free online surveys with eSurveysPro.com online survey software.